Lipid nanoparticles (LNPs) represent an extremely promising technology for delivery of gene products for a host of potential health applications, from immunization against emerging pathogens to personalized neoantigen cancer therapy and gene therapy for many diseases. Combining our industry-leading expertise in lipid chemistry, synthesis, and analysis with proficiencies in bioanalysis and cell biology, Cayman offers comprehensive services to support LNP development, characterization, and screening.